A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with R/R B-Cell Malignancies. - TITANium

Exclusion Criteria

• • Any neoplasm histology not specified in the IC section;
• • Active CNS involvement in lymphoma;
• • CNS pathology including but not limited to any history of seizure disorder/epilepsy;
• • Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;
• • History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS;
• • Active and uncontrolled infections;
• • Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions
• The above is a summary, other exclusion criteria details may apply.